Compare CCCC & UIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCCC | UIS |
|---|---|---|
| Founded | 2015 | 1942 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.3M | 260.2M |
| IPO Year | 2020 | N/A |
| Metric | CCCC | UIS |
|---|---|---|
| Price | $2.02 | $2.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $7.25 | $5.88 |
| AVG Volume (30 Days) | ★ 2.0M | 738.0K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $30,108,000.00 | ★ $1,921,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $2.37 |
| 52 Week High | $4.26 | $7.54 |
| Indicator | CCCC | UIS |
|---|---|---|
| Relative Strength Index (RSI) | 35.66 | 48.80 |
| Support Level | $2.00 | $2.77 |
| Resistance Level | $2.69 | $3.10 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 7.10 | 43.96 |
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. Majority of revenue is from ECS segment.